Hemodynamic effects of platelet-activating factor in nonpregnant and pregnant sheep

SUZANNE G. GREENBERG AND KENNETH E. CLARK
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267

Greenberg, Suzanne G., and Kenneth E. Clark. Hemodynamic effects of platelet-activating factor in nonpregnant and pregnant sheep. Am. J. Physiol. 277 (Regulatory Integrative Comp. Physiol. 46): R996–R1001, 1999.—The present study was designed to assess the dose-related effects of platelet-activating factor (PAF) on systemic, renal, and uterine hemodynamics in nonpregnant sheep and to evaluate how pregnancy might alter these responses. Nonpregnant and pregnant (110 ± 5 days gestation) ewes were instrumented for conscious measurements of maternal mean arterial pressure (MAP), renal blood flow (RBF), uterine blood flow (UBF), hematocrit, and urinary protein concentration. After recovery, dose-response curves to PAF were generated by systemic infusion at 10, 30, and 100 ng·kg⁻¹·min⁻¹ (15 min/dose) into the maternal femoral vein. The above parameters were measured, and renal and uterine vascular resistances (RVR and UVR, respectively) were calculated. In pregnant sheep, PAF increased MAP, RVR, UVR, and urinary protein concentration. We also observed increases in hematocrit, indicative of reduced blood volume secondary to increased systemic microvascular protein permeability. These responses were similar in nonpregnant sheep, with the exception of UVR in nonpregnant ewes being decreased (and thus UBF was increased), whereas in pregnant sheep, UVR was increased, which resulted in decreased UBF. This suggests that pregnancy alters the mechanism of action of PAF within the uterine vasculature in a way that can reduce UBF and thereby potentially compromise placental perfusion.

kidney; uterine vasculature; proteinuria; hematocrit

PLATELET-ACTIVATING FACTOR (PAF) is a low molecular weight phospholipid with a broad array of physiological actions. Classically, PAF has been regarded as mediator of inflammation that is produced by platelets, neutrophils, and macrophages. More recently, however, evidence has accumulated to show that PAF can have potent vasoactive effects and is synthesized by a number of nonimmune cell types such as endothelial (4), vascular smooth muscle (35), renal glomerular (7, 24), and amnion cells (10, 22). The effects of PAF on the vasculature appear to be somewhat complex in that this compound has demonstrated abilities as both a vasoconstrictor and vasodilator, seemingly dependent on dose, specific vascular bed, and species (2, 11, 16). In general, PAF appears to produce hypotension and decreased cardiac output; however, intrarenal infusion of PAF causes vasoconstriction in the dog kidney (2, 32) and mixed reports of either vasoconstriction or vasodilation in the rat kidney (1, 16, 33, 40).

Another important aspect of the actions of PAF is its ability to increase microvascular permeability, both systemically and within the kidney. This in regard, infusion of PAF is associated with both hemococoncentration and the development of proteinuria (18, 30). Although the mechanism for this effect is not entirely clear, it does appear to involve specific receptor-mediated events, because specific antagonists of PAF receptors have been shown to prevent PAF-induced protein extravasation across the systemic, pulmonary, and glomerular microvasculatures (6, 9, 26, 31).

Studies have shown that the production and metabolism of PAF is significantly influenced by changes in estrogen, progestins, and cytokines, all of which are central to the progression of pregnancy (36). This suggests that PAF may participate importantly in normal pregnancy as well as in certain complications of pregnancy. To begin to investigate the role of PAF in the regulation of cardiovascular hemodynamics in pregnancy, we sought to evaluate the actions of exogenously administered PAF on blood flow and vascular resistance as well as on microvascular permeability. The present studies were designed to assess the dose-related effects of PAF on systemic, renal, and uterine hemodynamics in nonpregnant sheep and to evaluate how pregnancy might alter these responses.

MATERIALS AND METHODS

Animals. Eight nonpregnant ewes (50–70 kg) and 13 pregnant ewes (110–115 days gestation) were purchased from Russell (Williamsburg, OH) and Morris (Reisterstown, MD), respectively. All animals were of similar mixed breed. Animals were housed in individual portable stainless steel cages in a temperature- and light-controlled American Association for Accreditation of Laboratory Animal Care accredited facility with free access to food and water.

Surgical procedures. Animals were sedated with pentobarbital sodium (15 mg/kg iv), and anesthesia was maintained by ventilation with a mixture of 2–3% isoflurane and oxygen. Under sterile conditions, the right kidney was exposed by a small retroperitoneal flank incision, and a transit-time Doppler flow probe (Transonic Systems, Ithaca, NY) was positioned on the renal artery for subsequent monitoring of unilateral renal blood flow (RBF). After a 1-wk recovery period, ewes were again anesthetized for abdominal preparation. In nonpregnant sheep, chronic indwelling polyvinyl catheters were implanted in the femoral artery and vein and advanced to the level of the distal aorta and vena cava, respectively. Through a 15-cm lower abdominal incision, transit-time Doppler flow probes were placed bilaterally on the main uterine arteries for measurement of uterine blood flow (UBF). Nonpregnant ewes were ovariecotomized to control exposure to sex steroids. Pregnant sheep were similarly instrumented with maternal...
ACUTE INFUSION OF PLATELET-ACTIVATING FACTOR IN SHEEP

R997

RESULTS

Both in nonpregnant and pregnant animals, short-term PAF infusion (15 min/dose) resulted in dose-dependent increases in MAP as is shown in Fig. 1. MAP tended to increase to a greater degree in nonpregnant compared with pregnant sheep. At the highest dose of PAF (100 ng·kg\(^{-1}\)·min\(^{-1}\)) the magnitude of this response became significantly different between the two groups, with MAP increasing 41 ± 9% from baseline (from 82 ± 5 to 115 ± 7 mmHg) in nonpregnant sheep compared with only 16 ± 8% from baseline (from 75 ± 2 to 87 ± 6 mmHg) in pregnant sheep.

PAF also caused significant vasoconstriction within the renal vasculature both in nonpregnant and pregnant sheep (Fig. 2). As illustrated, RVR increased in a dose-dependent manner in both groups. In nonpregnant sheep, RVR was significantly elevated from baseline at the two highest doses of PAF, whereas in pregnant sheep a significant effect was observed only at the highest dose. Although at the lower two doses of PAF, RVR tended to increase more in nonpregnant relative to pregnant animals, this difference was not statistically significant (P = 0.09 and 0.08, respectively). By the highest dose of PAF the magnitude of the response was nearly identical between the two groups. The dramatic increase in renal resistance observed at this dose (100 ng·kg\(^{-1}\)·min\(^{-1}\)) corresponded to only modest decreases in RBF (from 448 ± 55 to 403 ± 46 ml/min in nonpregnant ewes and from 466 ± 52 to 406 ± 75 ml/min in pregnant ewes). Thus, although the increase in vascular resistance in response to PAF indicates active vasoconstriction within the kidney, it would seem that the simultaneous increase in perfusion pressure afforded protection against a significant drop in RBF.

In the uterine vascular bed, an interesting dichotomy was observed with respect to the effects of PAF on vascular resistance and consequently on UBF. In nonpregnant animals, a marked dose-dependent decrease in UVR was observed in response to PAF infusion (Fig.
3), indicative of active vasodilation within the uterus. This was reflected by an increase in total UBF to ~3.5-fold over baseline by the highest PAF dose (from 21 ± 5 to 76 ± 15 ml/min; Fig. 4). In contrast to the response observed in nonpregnant ewes, pregnant sheep demonstrated a dose-dependent increase in UVR (and hence active constriction of the uterine vasculature) in response to PAF (Fig. 3). This corresponded to decreases in UBF by as much as 24 ± 7% below baseline by the highest dose of PAF (787 ± 65 to 637 ± 90 ml/min; Fig. 4). To address the possibility that this decrease in UBF was occurring secondary to contraction of the uterine smooth muscle, amniotic fluid pressure was measured in three animals as an index of intrauterine pressure. Amniotic fluid pressure remained quite stable throughout the PAF dose-response curve (range of 5 ± 1 to 8 ± 2 mmHg), thus indicating that the changes in UVR and UBF were not merely the result of uterine contraction.

Other hemodynamic effects of PAF included increases in microvascular permeability both in pregnant and nonpregnant sheep. At the systemic level this was suggested by an increase in hematocrit, which presumably resulted from protein and water leakage out of the vascular space, a previously documented effect of PAF (17). In nonpregnant sheep, hematocrit was significantly increased from baseline at 30 and 100 ng·kg⁻¹·min⁻¹ PAF, whereas in pregnant sheep the increase became significant at 100 ng·kg⁻¹·min⁻¹ PAF; at this highest PAF dose, hematocrit was elevated to a similar extent in both groups (nonpregnant 27 ± 1 to 33 ± 1%; pregnant 28 ± 3 ± 1%; Fig. 5). According to a mathematical derivation described by Van Beumont (37), the percent difference between the original and final hematocrit ratios can be used in conjunction with a proportionality factor to estimate the percent change in plasma volume. Thus, assuming that red blood cell volume remained constant throughout the experiment, the increases in hematocrit reflect a significant decrease in plasma volume, which was estimated to drop by 16 ± 2% in pregnant and 17 ± 2% in nonpregnant sheep by the end of the experiment.
Increased protein permeability was also evident within the kidney, as urinary protein excretion was elevated in nonpregnant sheep in response to the highest dose of PAF (Fig. 6). In pregnant sheep, baseline urinary protein excretion was somewhat higher than that of nonpregnant animals, as expected. In this group urinary protein excretion also tended to increase with the highest PAF dose, although this was not a significant elevation over baseline. The PAF-induced proteinuria, although somewhat variable between animals, is noteworthy in that it was observed after only 15 min of PAF infusion. It is possible that longer periods of PAF infusion may have elicited a more pronounced and consistent response.

DISCUSSION

The present studies were conducted to evaluate the effects of exogenously administered platelet-activating factor (PAF) on vascular tone and permeability in nonpregnant sheep and to determine if pregnancy alters these effects. In both nonpregnant and pregnant sheep, PAF was found to increase MAP in a dose-dependent fashion. This effect was somewhat surprising, because reports of PAF administration in other species are typically associated with hypotensive responses (19, 38). It is possible that the elevation in pressure observed in the present study was transient as each dose of PAF was maintained for only 15 min; longer term infusions may show changes in pressure secondary to the PAF-induced decrease in intravascular volume or may invoke more complex secondary vasoactive mechanisms. It is not clear from the present studies whether mediation of the observed hypertension is carried out by an endothelial (or perhaps platelet derived) vasoconstrictor or whether it is a direct effect of PAF.

Compelling evidence for the ability of pregnancy to alter vascular responsiveness to PAF was found in the sheep uterus. In nonpregnant animals, PAF administration produced a very clear dose-dependent uterine vasodilation, whereas, in pregnant sheep, quite the opposite response was observed. It is possible that the uterine vasculature may release a vasodilator in response to PAF in the nonpregnant but not in the pregnant state. However, preliminary experiments showed that in nonpregnant sheep the decrease in UVR was not altered by pretreatment with either nitro-ω-arginine methyl ester or indomethacin (13), suggesting that the PAF-induced vasodilation is not mediated by either nitric oxide or prostacyclin. In pregnant sheep, amniotic fluid pressure remained quite stable throughout the PAF dose-response curve, thus indicating that the observed increase in UVR and decreased UBF were not merely the result of uterine contraction but rather are reflective of active constriction of the uterine vasculature. One explanation for this is that pregnancy may upregulate receptor-mediated signalling mechanisms that specifically produce vasoconstriction. It is also possible that during pregnancy, PAF may modify its own actions by secondary stimulation of an endothelial vasoconstrictor within the uterine vasculature. This is of interest as it can be speculated that decreased capacity for compensatory endothelial cell vasodilator synthesis, as has been theorized to occur with preeclampsia, may amplify the ability of locally produced PAF to increase vascular tone and decrease blood flow in this bed. This is significant in that any mechanism that may potentially serve to decrease UBF during pregnancy could, over time, compromise placental perfusion and thereby reduce delivery of oxygen and nutrients to the developing fetus.

In the renal circulation, vasoconstriction was observed in both groups, as evidenced by progressively increased RVR and decreased RBF with each dose of PAF. These findings are consistent with those of Baer and Cagen (2), who found that equivalent doses of PAF infused directly into the renal artery in the dog constricted this vascular bed by ~15–20%. In that study, PAF-induced renal vasoconstriction appeared to be a direct, primary effect as it was not altered by blockade of suspected secondary mediators such as serotonin, angiotensin II, or alpha-adrenergic receptors, and was in fact potentiated by meclofenamate. This suggests that in addition to a direct effect on the vascular smooth muscle in the kidney, PAF may also stimulate the release of vasodilator prostaglandins, presumably from the endothelium.

To assess the effects of PAF on microvascular protein permeability, the present studies measured urinary protein excretion as a direct index of renal permeability and hematocrit as an indirect index of systemic permeability. The latter measurement must be somewhat cautiously interpreted because it is unknown whether PAF stimulates splenic contraction in the sheep, an effect that would independently increase hematocrit. However, it has been reported using direct measurement in the conscious sheep that PAF increases vascular leakage by significantly decreasing the protein reflection coefficient of the microvasculature (3). In addition, studies in rats and guinea pigs have shown similar increases in hematocrit in response to PAF administration (19). This can only reflect a decrease in
plasma volume because these species do not have the ability to alter hematocrit via splenic contraction. Thus, it is assumed that our observed rise in hematocrit, although possibly augmented by splenic release of red blood cells, was at least in part secondary to an increase in microvascular permeability.

Given this assumption it was found that, consistent with reports in other species, PAF significantly increased both systemic and renal glomerular microvascular permeability in the sheep, and this effect was not markedly different during pregnancy. Enhancement of microvascular permeability is an action of PAF that has been described by others (20, 28), and it appears that other agents that have also been observed to enhance vascular permeability, such as endothelin-1, vascular endothelial growth factor, and angiotensin II, may in fact share PAF as a common mediator of this effect (9, 29, 34). In support of this, previous studies from this laboratory that reported increases in systemic and renal vascular permeability induced by infusion of endothelin-1 in pregnant sheep (15) also observed that endothelin administration produced significant increases in plasma PAF (14). In general, it is thought that the PAF-stimulated increase in vascular protein permeability arises from a direct effect on venular endothelial cell contraction and formation of gap junctions leading to protein extravasation (39). A similar phenomenon is thought to occur in the kidney, where the mechanism of the proteinuric effect of PAF appears to involve rearrangement of cytoskeleton in endothelial and/or epithelial cells, resulting in an alteration of the size-selective properties of the glomerular barrier (30). It has been shown in the kidney as well as in other vascular beds that PAF-induced protein leakage is a specific, receptor-mediated event that is not inhibited by antagonists of cyclooxygenase or lipooxygenase or by pretreatment with antioxidants (9, 28, 34).

On the basis of the effects of PAF on vascular tone and permeability, it has been speculated that elevated production of PAF in certain disease states may play an important role in the progression of pathological conditions. In particular, PAF has been investigated as a potential mediator of various experimental models of progressive renal or diabetic renal disease (12, 27, 31) as well as gentamicin-induced nephrotoxicity (8). Additionally, blockade of PAF receptors has been shown to significantly delay the onset of proteinuria and prolong survival in lupus autoimmune mice (25). PAF has also been implicated in the pathophysiology of neonatal necrotizing enterocolitis (5) as well as various pulmonary diseases such as asthma, chronic obstructive pulmonary disease, lung fibrosis, and adult respiratory distress syndrome (21). Finally, although PAF is thought to be involved in a number of normal reproductive processes including ovulation, implantation, and parturition, it has been suggested that alterations in PAF production and/or metabolism may contribute to complications of pregnancy such as preeclampsia and preterm labor (23, 36). That PAF may participate importantly in normal pregnancy as well as in certain complications of pregnancy has been suggested by studies that show that the production and metabolism of PAF is significantly influenced by changes in estrogen, progestins, and cytokines, all of which are central to the progression of pregnancy (36). These observations also suggest, however, the possibility that the pharmacokinetics of PAF may be altered during pregnancy, which may have contributed to some of the quantitative differences between pregnant and nonpregnant sheep in the present study, particularly at the lower doses.

In summary, the results of the present study show that systemic administration of PAF in pregnant sheep produces increased maternal MAP, renal and uterine vascular resistances, and urinary protein excretion. We also observed marked increases in hematocrit, indicative of reduced blood volume secondary to increased systemic microvascular protein permeability. These responses were similar in nonpregnant sheep, with the exception that UVR was decreased in the nonpregnant sheep (thus UBF was increased), whereas UVR was increased in the pregnant sheep, resulting in decreased UBF. This suggests that pregnancy alters the mechanism of action of PAF within the uterine vasculature in a way that can reduce UBF and thereby potentially compromise placental perfusion.

The authors gratefully acknowledge R. S. Baker and A. Friedman for diligent assistance with the daily maintenance of animals used in this study.

This research was supported by National Heart, Lung, and Blood Institute Grants HL-56714, HL-49901, and HL-51051 and in part by the American Heart Association (Ohio).

Address for reprint requests and other correspondence: S. G. Greenberg, Dept. of Obstetrics and Gynecology, PO Box 670526, Univ. of Cincinnati, Cincinnati, OH 45267–0526.

Received 16 November 1998; accepted in final form 16 July 1999.

REFERENCES


